Human Molecular Genetics Advance Access originally published online on May 11, 2005
Human Molecular Genetics 2005 14(13):1863-1876; doi:10.1093/hmg/ddi192
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene expression in Huntington's disease skeletal muscle: a potential biomarker
1Clinical Research Division, 2Public Health Sciences Division, 3Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA, 4Department of Radiology, 5Department of Neurology, University of Washington, Seattle, WA 98195, USA, 6Department of Neuroscience, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK, 7University Department of Clinical Neurosciences, Royal Free and University College Medical School, UCL, London NW3 2PF, UK and 8Department of Neurodegenerative Disease/MRC Prion Unit Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
* To whom correspondence should be addressed. Tel: +1 2066675681; Fax: +1 2066672917; Email: astrand{at}fhcrc.org
Received March 29, 2005; Revised April 29, 2005; Accepted May 6, 2005
Huntington's disease (HD) is an incurable and fatal neurodegenerative disorder. Improvements in the objective measurement of HD will lead to more efficient clinical trials and earlier therapeutic intervention. We hypothesized that abnormalities seen in the R6/2 mouse, a greatly accelerated HD model, might highlight subtle phenotypes in other mouse models and human HD. In this paper, we identify common gene expression changes in skeletal muscle from R6/2 mice, HdhCAG(150) homozygous knock-in mice and HD patients. This HD-triggered gene expression phenotype is consistent with the beginnings of a transition from fast-twitch to slow-twitch muscle fiber types. Metabolic adaptations similar to those induced by diabetes or fasting are also present but neither metabolic disorder can explain the full phenotype of HD muscle. The HD-induced gene expression changes reflect disease progression. This raises the possibility that muscle gene expression may be used as an objective biomarker to complement clinical HD-rating systems. Furthermore, an understanding of the molecular basis of muscle dysfunction in HD should provide insight into mechanisms involved in neuronal abnormalities and neurodegeneration.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. K. Chaturvedi, P. Adhihetty, S. Shukla, T. Hennessy, N. Calingasan, L. Yang, A. Starkov, M. Kiaei, M. Cannella, J. Sassone, et al. Impaired PGC-1{alpha} function in muscle in Huntington's disease Hum. Mol. Genet., August 15, 2009; 18(16): 3048 - 3065. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Phan, M. A. Hickey, P. Zhang, M.-F. Chesselet, and K. Reue Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models Hum. Mol. Genet., March 15, 2009; 18(6): 1006 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Fang, A. Strand, W. Law, V. M. Faca, M. P. Fitzgibbon, N. Hamel, B. Houle, X. Liu, D. H. May, G. Poschmann, et al. Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease Mol. Cell. Proteomics, March 1, 2009; 8(3): 451 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Lalic, J. Maric, M. Svetel, A. Jotic, E. Stefanova, K. Lalic, N. Dragasevic, T. Milicic, L. Lukic, and V. S. Kostic Glucose Homeostasis in Huntington Disease: Abnormalities in Insulin Sensitivity and Early-Phase Insulin Secretion Arch Neurol, April 1, 2008; 65(4): 476 - 480. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Runne, A. Kuhn, E. J. Wild, W. Pratyaksha, M. Kristiansen, J. D. Isaacs, E. Regulier, M. Delorenzi, S. J. Tabrizi, and R. Luthi-Carter Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood PNAS, September 4, 2007; 104(36): 14424 - 14429. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zuccato, N. Belyaev, P. Conforti, L. Ooi, M. Tartari, E. Papadimou, M. MacDonald, E. Fossale, S. Zeitlin, N. Buckley, et al. Widespread Disruption of Repressor Element-1 Silencing Transcription Factor/Neuron-Restrictive Silencer Factor Occupancy at Its Target Genes in Huntington's Disease J. Neurosci., June 27, 2007; 27(26): 6972 - 6983. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zourlidou, T. Gidalevitz, M. Kristiansen, C. Landles, B. Woodman, D. J. Wells, D. S. Latchman, J. de Belleroche, S. J. Tabrizi, R. I. Morimoto, et al. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation Hum. Mol. Genet., May 1, 2007; 16(9): 1078 - 1090. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tagawa, S. Marubuchi, M.-L. Qi, Y. Enokido, T. Tamura, R. Inagaki, M. Murata, I. Kanazawa, E. E. Wanker, and H. Okazawa The Induction Levels of Heat Shock Protein 70 Differentiate the Vulnerabilities to Mutant Huntingtin among Neuronal Subtypes J. Neurosci., January 24, 2007; 27(4): 868 - 880. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Benn, C. Landles, H. Li, A. D. Strand, B. Woodman, K. Sathasivam, S.-H. Li, S. Ghazi-Noori, E. Hockly, S. M.N.N. Faruque, et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease Hum. Mol. Genet., October 15, 2005; 14(20): 3065 - 3078. [Abstract] [Full Text] [PDF] |
||||




